Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$2.61 +0.4%	$2.01	$1.09 ▼ $7.22	$185.04M	2.97	1.64 million shs	610,102 shs
KLRS Kalaris Therapeutics	$2.46 -4.3%	$2.56	$2.14 ▼ $24.15	$48.06M	0.49	48,385 shs	10,797 shs
SLS SELLAS Life Sciences Group	$1.76 -4.9%	$1.79	$0.77 ▼ $2.27	$194.80M	2.26	1.79 million shs	1.70 million shs
TVGN Tevogen Bio	$0.90 -1.6%	$1.11	$0.26 ▼ $3.09	$169.02M	-0.77	1.47 million shs	216,854 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	+0.38%	+11.06%	+17.57%	+89.13%	-58.64%
KLRS Kalaris Therapeutics	-4.28%	+8.37%	-4.28%	+245,999,900.00%	+245,999,900.00%
SLS SELLAS Life Sciences Group	-4.86%	+13.55%	-4.35%	-6.88%	+34.35%
TVGN Tevogen Bio	-1.60%	-7.71%	-18.52%	-30.96%	+46.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CCCC C4 Therapeutics	1.2454 of 5 stars	3.2	2.0	0.0	1.7	0.0
KLRS Kalaris Therapeutics	1.3023 of 5 stars	2.0	0.0	1.6	3.3	0.6
SLS SELLAS Life Sciences Group	2.8547 of 5 stars	3.5	2.0	3.8	1.7	0.6
TVGN Tevogen Bio	3.9449 of 5 stars	3.5	3.0	3.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.33	Hold	$8.00	206.51% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	21.95% Upside
SLS SELLAS Life Sciences Group	3.00	Buy	$7.00	297.73% Upside
TVGN Tevogen Bio	3.00	Buy	$10.00	1,005.71% Upside

Current Analyst Ratings Breakdown

Latest KLRS, CCCC, TVGN, and SLS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/4/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
7/16/2025	SLS SELLAS Life Sciences Group	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $7.00
6/18/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/27/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.58M	5.22	N/A	N/A	$2.45 per share	1.07
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
SLS SELLAS Life Sciences Group	$1M	185.33	N/A	N/A	$0.25 per share	7.04
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($0.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$105.32M	-$1.58	N/A	N/A	N/A	-325.88%	-53.91%	-33.26%	10/30/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
SLS SELLAS Life Sciences Group	-$30.88M	-$0.32	N/A	N/A	N/A	N/A	-132.51%	-92.79%	N/A
TVGN Tevogen Bio	-$13.73M	N/A	0.00	∞	N/A	N/A	N/A	-775.49%	N/A

Latest KLRS, CCCC, TVGN, and SLS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2025	N/A	TVGN Tevogen Bio	-$0.05	-$0.03	+$0.02	-$0.03	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/12/2025	Q2 2025	SLS SELLAS Life Sciences Group	-$0.0767	-$0.07	+$0.0067	-$0.07	N/A	N/A
8/7/2025	Q2 2025	CCCC C4 Therapeutics	-$0.38	-$0.37	+$0.01	-$0.37	$5.24 million	$6.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
SLS SELLAS Life Sciences Group	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.06	5.06
KLRS Kalaris Therapeutics	N/A	11.98	11.98
SLS SELLAS Life Sciences Group	N/A	4.91	4.91
TVGN Tevogen Bio	N/A	0.26	0.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
KLRS Kalaris Therapeutics	66.05%
SLS SELLAS Life Sciences Group	17.38%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	8.73%
KLRS Kalaris Therapeutics	74.99%
SLS SELLAS Life Sciences Group	1.40%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	71.17 million	64.96 million	Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
SLS SELLAS Life Sciences Group	10	105.30 million	103.82 million	Not Optionable
TVGN Tevogen Bio	3	183.89 million	49.21 million	N/A

KLRS, CCCC, TVGN, and SLS Headlines

Recent News About These Companies

Tevogen Bio (NASDAQ:TVGN) Announces Earnings Results

August 21 at 5:28 PM | marketbeat.com

D. Boral Capital Reiterates Buy Rating for Tevogen Bio (NASDAQ:TVGN)

August 20 at 8:24 AM | marketbeat.com

Tevogen finalizes agreement for up to $50M in financing

August 19 at 10:15 PM | msn.com

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance ...

August 19 at 5:14 PM | bakersfield.comB

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

August 19 at 3:40 PM | globenewswire.com

Tevogen Bio Holdings Inc. Reports Q2 2025 Financial Results with Reduced Loss from Operations and Focus on Growth Strategy

August 19 at 12:52 PM | quiverquant.comQ

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

August 19 at 12:10 PM | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

August 18, 2025 | globenewswire.com

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

August 18, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Stock Price Down 3% - Here's What Happened

August 16, 2025 | marketbeat.com

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

August 14, 2025 | globenewswire.com

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 13, 2025 | globenewswire.com

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

August 11, 2025 | globenewswire.com

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

August 11, 2025 | globenewswire.com

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

August 11, 2025 | globenewswire.com

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

August 11, 2025 | globenewswire.com

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 8, 2025 | globenewswire.com

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

August 7, 2025 | globenewswire.com

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

August 6, 2025 | globenewswire.com

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

August 5, 2025 | globenewswire.com

Semper Paratus Acquisition (NASDAQ:TVGN) Given Buy Rating at D. Boral Capital

August 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KLRS, CCCC, TVGN, and SLS Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$2.61 +0.01 (+0.38%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$2.59 -0.02 (-0.77%)

As of 08/21/2025 07:52 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kalaris Therapeutics NASDAQ:KLRS

$2.46 -0.11 (-4.28%)

As of 08/21/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

SELLAS Life Sciences Group NASDAQ:SLS

$1.76 -0.09 (-4.86%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.00 (+0.23%)

As of 08/21/2025 08:00 PM Eastern

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Tevogen Bio NASDAQ:TVGN

$0.90 -0.01 (-1.60%)

Closing price 08/21/2025 04:00 PM Eastern

Extended Trading

$0.91 +0.01 (+1.06%)

As of 08/21/2025 07:59 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time